Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
Phase 2
Withdrawn
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05809895
Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients
Completed
- Conditions
- BRAF v600 Mutated Metastatic Melanoma
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT05806268
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 700
- Registration Number
- NCT05803941
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸St. Joseph Hospital, Orange, California, United States
🇺🇸Providence Saint Johns Health Ctr, Santa Monica, California, United States
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Phase 1
Active, not recruiting
- Conditions
- Lupus NephritisSystemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT05798117
- Locations
- 🇺🇸
Division of Rheumatology Immunology, Birmingham, Alabama, United States
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT05795153
- Locations
- 🇺🇸
Acuro Research Inc, Little Rock, Arkansas, United States
🇺🇸Florida Ctr Allergy Asthma Research, Aventura, Florida, United States
🇺🇸Finlay Medical Research, Greenacres City, Florida, United States
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Phase 3
Recruiting
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Drug: Iptcaopan 200 mg
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT05795140
- Locations
- 🇮🇳
Novartis Investigative Site, Pune, Maharashtra, India
Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations
Completed
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 Mutations
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT05796726
- Locations
- 🇩🇪
Novartis Investigative Site, Würzburg, Germany
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
Phase 3
Withdrawn
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05791097
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Completed
- Conditions
- Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT05787236
- Locations
- 🇮🇩
Mangga Besar Clinic, Jakarta, Indonesia
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Phase 3
Not yet recruiting
- Conditions
- Asthma
- Interventions
- Drug: Placebo to QVM149Drug: Run-In MedicationDrug: Rescue MedicationDevice: Concept 1 DeviceDevice: Girohaler
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 304
- Registration Number
- NCT05776927
© Copyright 2025. All Rights Reserved by MedPath